The use of accurate biomarkers for detecting autism spectrum disorder could result in saving billions of dollars in healthcare costs, according to a paper recently published in the journal Autism Research.
The use of accurate biomarkers for detecting autism spectrum disorder (ASD) could result in saving billions of dollars in healthcare costs, according to a paper recently published in the journal Autism Research.
The paper titled, "Evidence–based Use of Scalable Biomarkers to Increase Diagnostic Efficiency and Decrease the Lifetime Costs of Autism," showed if more children with ASD are identified early and referred for early intervention services, government supported healthcare and educational systems would realize substantial cost savings of more than $30 billion/year.
The study looked at two recently researched and published biomarker technologies, a molecular saliva test and a remote eye gaze tracking technology. The research study was a collaborative effort with several leading autism researchers and clinicians, including Autism Speaks' Chief Science Officer and John Carroll University Professor Thomas Frazier PhD, ECHO Autism founder and University of Missouri School of Medicine Professor Kristin Sohl MD, and The Ohio State University College of Medicine Professor Daniel Coury MD.
Approximately 1 in 54 American children are currently diagnosed with ASD, a 10-fold increase in prevalence over the past 40 years. Unfortunately, this high rate of autism in the U.S., when combined with a relatively small number of specialists trained to make the diagnosis, has resulted in long wait times for families to receive an autism evaluation. Consequently, while diagnosis is possible in children as young as 18 months, the average age of ASD diagnosis in the United States today often exceeds 4 years of age. Early diagnosis is important because intensive behavioral therapy has been shown to improve the symptoms of autism, and children benefit more from such intervention the earlier it is started.
The researchers in this study sought to assess the financial impact of initiating appropriate interventions faster and reducing the number of unnecessary diagnostic evaluations, through the adoption of accurate biomarkers. The study focused on two recently researched and published biomarker technologies: a molecular saliva test and a remote eye gazing tracking technology. These particular biomarker tests were selected because of their scalability and ease of implementation.
The study estimated lifetime societal cost savings in special education, medical and residential care, to be nearly $580,000 per ASD child, with annual cost savings in education exceeding $13.3 billion, and annual cost savings in medical and residential care exceeding $23.8 billion (of these, nearly $11.2 billion are attributable to Medicaid). These savings total more than $37 billion/year in societal savings in the US.
"This study shows how implementing an accurate diagnostic measure to high risk cases initially flagged from screening tools, can further inform clinical judgment and substantially improve early identification," said Dr. Thomas Frazier, one of the principal authors on the paper. "Our findings demonstrate the positive clinical and financial influences that implementing measures that inform ASD diagnosis can have, reinforcing the need to continue development of accurate, scalable biomarkers for ASD, such as these molecular and eye-tracking technologies."
Dupixent Is Linked to a Higher Risk of Psoriasis in Patients With Atopic Dermatitis
July 8th 2025AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and psoriasis driven by Th17 inflammation. However, newer research has shown that these diseases can overlap in patients and may even share common pathways.
Read More
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Autoimmune Diseases Almost Double Mental Health Disorder Risk
July 7th 2025The prevalence of autoimmune disease patients with a mental health disorder is almost twice the number of patients without, suggesting there is a link between inflammation and conditions such as depression, anxiety disorder and bipolar disorder.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen